


## 8TH AFRCP DAY



# WEDNESDAY, SEPTEMBER 25, 2024

## PALLADIA HOTEL, TOULOUSE



### SELECTED SHORT TALKS



#### MALNUTRITION, THE DARK SIDE OF CANCER?

Dr. Stéphane SERVAIS – N2C, Tours



#### L'IMAGERIE AU SERVICE DE LA DÉTECTION DE LA SARCOPÉNIE

Drs. Christophe MANCEAU & Franck  
ESPINOSA – IPC, Marseille



### CALL FOR PROJECT WINNERS



#### NEURAL REMODELING AND PERI-NEURAL INVASION: NEW PLAYERS IN PANCREATIC CANCER AGGRESSIVENESS

Dr. Richard TOMASINI – CRCM, Marseille



#### THE SEARCH FOR TREATMENTS TO REDUCE CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY

Pr. Romain CORIAT – CHU Cochin, Paris

REGISTER  
*at*



MORE  
INFO



FOLLOWED BY THE 38TH MEETING OF CFP  
(26-27TH OF SEPTEMBER)





**8<sup>th</sup> Scientific Day**  
**September 25, 2024, Toulouse**  
**Palladia Hotel**

---

9:00 – 9:30	<b>Registration and Welcome coffee</b>
-------------	--

9:30 – 9:45	<b>Welcome introduction</b> <b>Barbara BOURNET</b> – CRCT/CHU Rangueil, Toulouse
-------------	---

9:45– 11:00	<p><b>Session 1 – Treatment resistance</b></p> <ul style="list-style-type: none"> <li>- Deep learning for prediction of chemotherapy response from histopathology in pancreatic cancer. <b>Audrey BEAUFILS</b> – CRI, Beaujon</li> <li>- PANCprofiler: an intratumoral stratifier unravels novel pancreatic cancer treatment-resistant cell phenotypes. <b>Nicolas FRAUNHOFFER</b> – CRCM, Marseille</li> <li>- Impact of Organoid-derived Extracellular Vesicles on CAFs and Matrix: Correlation with therapeutic resistance in PDAC. <b>Christopher ROVERA</b> – CRCM, Marseille</li> <li>- Intérêt du ciblage thérapeutique de la mucine MUC4 dans l'adénocarcinome pancréatique en tant que plateforme d'interaction avec les récepteurs à tyrosine kinase. <b>Tristan GIRGIN</b> – CANTHER, Lille (Lauréat 2022)</li> <li>- Metabolic rewiring in response to chemotherapy in pancreatic ductal adenocarcinoma (PDAC). <b>Elodie METAY</b> – CRCM, Marseille</li> </ul>
-------------	--

11:00 – 12:05	<p><b>Keynote 1</b></p> <p>- <b>Malnutrition, the dark side of cancer?</b> <b>Dr. Stéphane SERVAIS</b> – N2C, Tours</p>
---------------	---

	<p>- <i>L'imagerie au service de la détection de la sarcopénie</i></p> <p><b>MM Christophe MANCEAU &amp; Franck ESPINOSA</b> – IPC, Marseille</p> <p>- Integrative study of skeletal muscle mitochondrial dysfunction in a murine pancreatic cancer-induced cachexia model. <b>Tristan GICQUEL</b> – CRCM, Marseille</p>
--	--

12:05 – 13:30	<b>Lunch Break – Poster Session – Sponsor's Tour</b>
---------------	--

13:30 – 14:40	<p><b>Keynote 2</b></p> <p>- <i>Neural remodeling and peri-neural invasion: new players in pancreatic cancer aggressiveness</i></p> <p><b>Dr. Richard TOMASINI</b> – CRCM, Marseille</p> <p>- <i>The search for treatments to reduce chemotherapy-induced peripheral neuropathy</i></p> <p><b>Pr. Romain CORIAT</b> – CHU Cochin, Paris</p> <p>- Matrix stiffness and its impact on cancer innervation. <b>Karen SLEIMAN</b> – IBDM, Marseille</p>
---------------	--

14:40 – 15:40	<p><b>Session 3 – Innovative approaches</b></p> <p>- Modelling the initiation of Pancreatic Ductal Adenocarcinoma using an Amphicrine Pancreas on Chip. <b>Pierre CAULLET</b> – IRIG/BGE, Grenoble</p> <p>- Tumoral mechanical stress reprograms adjacent tissue micro-environment to fuel pancreatic tumor progression: identification of a new subtype of activated fibroblasts. <b>Claire LAC</b> – CRCT, Toulouse</p> <p>- Deciphering the intratumoral molecular heterogeneity of pancreatic adenocarcinoma by artificial intelligence. <b>Taib BOUREGA</b> – CRI, Beaujon</p> <p>- The role of ER-localised O-glycosylation in pancreatic cancer. <b>Rebecca BENNION</b> – CRCM, Marseille</p>
---------------	--

15:40 – 16:00	<b>AFRCP general assembly</b>
---------------	-------------------------------

16:00 – 16:30	<b>Coffee Break</b>
---------------	---------------------

16:30 – 18:00	<p><b>Session 4 – Immune microenvironment</b></p> <ul style="list-style-type: none"> <li>- Role of CDKN2A in the regulation of the immune tumor micro-environment in mouse models of pancreatic ductal adenocarcinoma (PDAC). <b>Jeanne MAGNAN</b> – IRMB, Créteil</li> <li>- La réponse à l'IFN<math>\gamma</math> dans les interactions tumeur/stroma d'un nouveau sous-type d'Adénocarcinome Pancréatique : peptides antigéniques et CAF présentateur d'Antigène. <b>Mehdi LIAUZUN</b> – CRCT, Toulouse</li> <li>- Role of BIGH3/Notch-1 signalling in the mechanics of stroma and its reprogramming in pancreatic cancer. <b>Donia SAIB</b> – CRCL, Lyon</li> <li>- Inhibiting epigenetic factors to promote anti-tumour immunity and to overcome resistance to therapy in pancreatic cancer. <b>Fanny HILDAGO-VILLEDA</b> – CRCM, Marseille</li> <li>- Pancreatic cancer immuno-permissiveness shaping by gene therapy. <b>Julia ROSSI</b> – BRIC, Bordeaux (Lauréate 2022)</li> <li>- Targeting mitochondrial metabolism in the crosstalk between tumor cells and their immune environment in pancreatic cancer. <b>Scarlett GALLARDO-ARRIAGA</b> – CRCM, Marseille (Lauréate 2022)</li> </ul>
---------------	--

**Partenaires de la journée :**

